VTE rates not significantly reduced by apixaban in paediatric ALL or lymphoma
Apixaban does not significantly reduce the rate of venous thromboembolism relative to standard care in paediatric patients with acute lymphoblastic leukaemia or lymphoma, show data from the phase 3 PREVAPIX-ALL trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.